BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products
BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products
Monday, BioNTech SE (NASDAQ:BNTX) reported deeper losses in the second quarter of 2024, with an EPS loss of $(3.62) or (3.36) euros, missing the consensus of (1.89) euros and higher than (79) cents in the second quarter of 2023.
BioNTech SE(NASDAQ:BNTX)於2024年第二季度報告了更深的虧損，每股收益爲$(3.62)或(3.36)歐元，低於共識的(1.89)歐元，高於2023年第二季度的(79)美分。
The company reported a net loss of 807.8 million euros compared to 190.4 million euros a year ago.
該公司報告的淨虧損爲8,078萬歐元，相比去年的1,904萬歐元有所增加。
The COVID-19 vaccine maker reported sales of 128.7 million euros ($138.56 million), down from 167.7 million euros a year ago and missing the consensus of 157 million euros, reflecting a continued shift in demand from a pandemic to a seasonal endemic COVID-19 vaccine market.
這個生物-疫苗製造商的銷售額爲1,287萬歐元($138.56萬美元)，低於去年的16,770萬歐元，未達到共識的15,700萬歐元，反映出從流行病到季節性免疫COVID-19疫苗市場需求的持續轉移。
Also Read: Why Is Pfizer Partner BioNTech Stock Trading Lower On Monday?
另請閱讀：爲什麼輝瑞合作伙伴BioNTech股票週一交易走低？
"The year to date has been marked by significant data updates across our oncology portfolio. These readouts reinforce the potential of our platform technologies, including our individualized and off-the-shelf mRNA vaccine platforms, iNeST and FixVac. We have also advanced our strategy by initiating clinical trials evaluating novel combinations of synergistic drug candidates," said Ugur Sahin, CEO and Co-Founder of BioNTech.
“年初至今，我們的腫瘤學組合領域的重要數據不斷更新。這些數據驗證了我們平台技術的潛力，包括個性化和即用型mRNA疫苗平台，iNeSt和FixVac。我們還通過啓動臨床試驗，評估了協同藥物候選人的新型組合，推進了我們的策略。”BioNTech的首席執行官兼聯合創始人Ugur Sahin表示。
"In addition, we have started commercializing variant-adapted COVID-19 vaccines for the upcoming season while accelerating our clinical development efforts to realize the full potential of our technologies," Sahin added.
“此外，我們已經開始銷售針對即將到來的季節性變異COVID-19疫苗，同時加速我們的臨床開發工作，實現我們技術的全部潛力。”Sahin補充道。
R&D expenses increased from 373.4 million euros to 584.6 million euros, mainly influenced by progressing clinical studies for the company's late-stage oncology pipeline candidates.
研發費用從3,734萬歐元增加到5,846萬歐元，主要是由於推進公司晚期腫瘤學候選線的臨床研究所致。
On Monday, Genmab A/S (NASDAQ:GMAB) announced that it will assume sole responsibility for developing and potentially commercializing acasunlimab as BioNTech has opted not to participate in the further development of the acasunlimab program.
週一，Genmab A / S（納斯達克：GMAB）宣佈，由於BioNTech選擇不參與acasunlimab計劃的進一步發展，因此將獨自負責開發和潛在的商業化acasunlimab。
The program will be subject to payment of certain milestones and a tiered single-digit royalty on net sales by Genmab to BioNTech.
該計劃將取決於Genmab向BioNTech支付一定的里程碑以及按淨銷售額支付的分層單位在BioNTech的單個Comirnaty-COVID-19疫苗合作項目中。
Genmab plans to initiate the Phase 3 study in the second half of this year.
Genmab計劃在今年下半年啓動第3階段研究。
BioNTech informed the company that it made the decision relating to its portfolio strategy.
BioNTech表示，它是基於組合策略作出決定的。
Guidance: BioNTech said it is still targeting 2024 revenues of 2.5 billion euros to 3.1 billion euros.
指導意見：BioNTech表示，仍然目標2024年收入爲25億歐元至31億歐元。
Partner Pfizer Inc. (NYSE:PFE) raised its 2024 guidance to $8.5 billion from $8 billion but reaffirmed that $5 billion would come from BioNTech's partnered Comirnaty-COVID-19 vaccine.
合作伙伴輝瑞公司（NYSE: PFE）將其2024年業績預期從80億美元上調至85億美元，但重申其中500億美元將來自BioNTech合作的Comirnaty-COVID-19疫苗。
Moderna Inc (NASDAQ:MRNA) lowered its 2024 sales guidance on Thursday due to weaker demand for its COVID-19 vaccines.
由於COVID-19疫苗的需求疲軟，Moderna Inc（納斯達克：MRNA）在週四下調了2024年的銷售預期。
Price Action: BNTX stock is down 4.08% at $78.66 during the premarket session at last check Monday.
最近一次覈查顯示，BNTX股票在週一盤前交易中下跌4.08%，至每股78.66美元。
- London High Court Ruling Fuels Pfizer And Moderna Legal Dispute Over COVID-19 Vaccine Patents.
- 倫敦高等法院的裁決加劇了輝瑞和Moderna公司之間的針對COVID-19疫苗專利的法律糾紛。
Photo via Wikimedia Commons
照片通過Wikimedia Commons